At this year’s American College of Cardiology Scientific Sessions in Chicago, USA (29-31 March 2025), Lp(a) research highlights included results of the Phase 2 ALPACA trial of lepodisiran, the impact of Lp(a) testing on cardiovascular (CV) event reduction, and reasons why testing is not more widespread. In addition, researchers presented data showing the importance of Lp(a) in diabetic retinopathy, the effects of Lp(a) on plaque, and clues that inhibition of Lp(a) oxidation may have contributed to the CV benefits shown in REDUCE-IT in patients with hypertriglyceridaemia.
Reports by Jenny Bryan
- ALPACA trial shows sustained Lp(a) reductions with lepodisiran
- Lp(a) testing linked to CV event reduction
- Importance of Lp(a) in diabetic retinopathy
- What is the effect of Lp(a) on plaque?
- Plasma Lp(a) oxidation provides fresh clues to REDUCE-IT benefits
- Olezarsen remodels Lp(a) particles by reducing TG content
